Form 4: Allogene Therapeutics Executive Acquires Shares and Stock Options

Allogene Therapeutics' SVP, General Counsel, Earl Douglas Martin, acquired 144,928 shares and 512,370 stock options on January 24, 2025.

Summary

• On January 24, 2025, Earl Douglas Martin, SVP, General Counsel of Allogene Therapeutics, acquired 144,928 shares of common stock.
• These shares were acquired at a price of $0.
• Mr. Martin also acquired 512,370 stock options with an exercise price of $1.94.
• The stock options vest over time, with 25% vesting on January 24, 2026, and the remaining vesting in 36 equal monthly installments thereafter.
• Following these transactions, Mr. Martin directly owns 594,252 shares and 512,370 stock options.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a standard executive transaction. It is neither particularly positive nor negative.

Positives

• The acquisition of shares and stock options by a high-ranking executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• Stock option grants and share acquisitions are common forms of executive compensation in the biotechnology industry.
• The vesting schedule of the stock options is typical, with a portion vesting after one year and the remainder vesting over the following years.
• The exercise price of $1.94 is a standard practice for stock options.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates executive confidence in the company.

Key Dates

Keywords

Allogene Therapeutics, stock options, share acquisition, insider trading, executive compensation, equity, ALLLO